Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response
Titel:
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response
Auteur:
Rody, A. Karn, T. Gätje, R. Ahr, A. Solbach, C. Kourtis, K. Munnes, M. Loibl, S. Kissler, S. Ruckhäberle, E. Holtrich, U. von Minckwitz, G. Kaufmann, M.